**SUPPLEMENTAL TABLES**

**Table of Content:**


| | | Page |
|---|---|---|
| Supplemental Table 1. | Basic patients characteristics of the cohort used for serum HGF measurements. | 3 |
| Supplemental Table 2. | Patients characteristics of second TMA. | 4 |
| Supplemental Table 3. | Genes with significantly ($P \leq 0.05$, absolute value of log ratio > 0.1) changed expression in tumors from ACC patients (dataset GSE10927) relative to expression in normal adrenocortical tissues. | 6 |
| Supplemental Table 4. | Biological processes Significantly ($P<0.05$) changed in tumors from ACC patients with high *MET* expression relative to tumors with low *MET* expression (dataset GSE10927) as presented in Figure 2a. | 496 |
| Supplemental Table 5. | Genes significantly ($P \leq 0.05$, absolute value of log ratio > 0.1) changed in tumors from ACC patients with high *MET* expression compared to those with low *MET* expression (dataset GSE10927). | 498 |
| Supplemental Table 6. | Gene set enrichment analysis of ACC patients' cohort for genes related to cell proliferation (dataset GSE10927). | 602 |

| | | |
|---|---|---|
| Supplemental Table 7. | Gene set enrichment analysis of ACC patients' cohort for genes related to the negative regulation of cell apoptosis (dataset GSE10927). | 613 |
| Supplemental Table 8. | Gene set enrichment analysis of ACC patients' cohort for genes related to cell proliferation (dataset GSEA49278). | 616 |
| Supplemental Table 9. | Gene set enrichment analysis of ACC patients' cohort for genes related to the negative regulation of cell apoptosis (dataset GSEA49278). | 626 |
| Supplemental Table 10. | Drug metabolism-related genes with significantly ($P \leq 0.05$, absolute value of log ratio > 0.1) changed expression in tumors from ACC patients (dataset GSE10927) with high *MET* expression relative to those with low *MET* expression. | 629 |
| Supplemental Table 11. | Gene set enrichment analysis detail of ACC patients' cohort for genes associated with resistance and metabolism of cisplatin, etoposide and doxorubicin (dataset GSEA10927). | 773 |
| Supplemental Table 12. | Gene set enrichment analysis detail of ACC patients' cohort for genes associated with resistance and metabolism of cisplatin, etoposide and doxorubicin (dataset GSEA49278). | 775 |